Feature Ritter Pharma aims to have first FDA-approved treatment for lactose intolerance By Len Zehr Ritter Pharmaceuticals’ (NASDAQ:RTTR) lead product candidate, RP-G28, which recently entered Phase 3 clinical trials, has the potential to become the first prescription therapy for lactose intolerance, a... September 4, 2018